Skip to main content

Advertisement

Table 3 Baseline minority resistance mutations detected by ultra-deep sequencing

From: Pre-treatment minority HIV-1 drug resistance mutations and long term virological outcomes: is prediction possible?

ID Virological outcome after at least 6 months of HAART Genotype Baseline resistance mutations (% prevalence) Drug activity of initiated regimen (Based on drug resistance mutation surveillance list [31]) Drug activity of initiated regimen (Based on impact of treatment efficacy Stanford HIVdb algorithm)
NRTIs NNRTIs TAMS
L001 Suppressed C D67E (1.67)
T69N (1.25)
F77L (2.16)
P225H (1.35)
F227L (2.36)
1 TDF and FTC resistance
EFV resistance
TDF susceptible
FTC susceptible
EFV resistance
L009 Detectable viremia (<1000 RNA copies/ml) C D67E (1.29)
T69N (1.03)
F77L (1.15)
L100I (1.15)
KI03N (4.17)
F227L (1.49) 1 TDF and FTC resistance
EFV resistance
TDF susceptible
FTC susceptible
EFV high level resistance
L013 Virological failure C D67E (1.73)
T69N (1.21)
F77L (1.13)
P225H (1.16)
F227L (1.98)
1 TDF and FTC resistance
EFV resistance
TDF susceptible
FTC susceptible
EFV low level resistance
L031 Virological failure C D67E (1.05)
F77L (1.02)
F227L (1.78) 1 TDF and FTC susceptible
EFV resistance
TDF susceptible
FTC susceptible
EFV resistance
L054 Virological failure C A62V (1.51)
D67E (1.16)
F77L (1.52)
F227L (1.26) 1 TDF resistance and FTC susceptible
EFV resistance
TDF resistance
FTC susceptible
EFV resistance
L064 Virological failure C D67E (1.32) F227L (1.43) 1 TDF and FTC susceptible
EFV susceptible
TDF susceptible
FTC susceptible
EFV resistance
L074 Suppressed CRF37_cpx D67E (1.72)
T69N (1.34)
M184I (1.04)
P225H (1.12)
F227L (1.86)
1 TDF and FTC resistance
EFV resistance
TDF susceptible
FTC resistance
EFV resistance
L075 Suppressed CRF37_cpx D67E (1.83)
T69N (1.58)
L74V (1.23)
F77L (1.01)
M184I (1.44)
P225H (2.22)
F227L (1.47)
1 TDF and FTC resistance
EFV resistance
TDF susceptible
FTC resistance
EFV low level resistance